Quinn
ActiveThe AI that delivers pharma R&D decisions in days, not months
This company has previously operated under “iollo”. A rename frequently marks a pivot in positioning or product — useful raw material for variant ideas.
About
Quinn makes the highest-stakes scientific decisions in drug development. Which drugs to bet on, what to develop next, how to get them to patients. In days instead of months.
Founders · 1
Daniel Gomari is the founder and CEO of Quinn. A Stanford postdoc and PhD in Computational Biology, his work spanned ML for drug repurposing across cancer and metabolic disease, and multi-omics studies on aging and lifespan extension. He built Quinn after watching the pharma industry make billion-dollar R&D decisions on intuition and slide decks instead of computational evidence.
Related startups
AI Agents for Pharma Drug Launches
Sales AI that helps revenue teams move faster and close more deals.
